Previous 10 | Next 10 |
Aspire Capital Fund has entered into an agreement to purchase up to $20M of ordinary share of VBL Therapeutics (VBLT)Proceeds from any sales of ordinary shares will be used for working capital and for general corporate purposes. “This Purchase Agreement provides VBL the opportunity to ...
TEL AVIV, Israel, Jan. 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications, tod...
VBL Therapeutics (VBLT) has announced that it has enrolled the first patient in Europe in the ongoing Phase 3 study for VB-111 for platinum-resistant ovarian cancer.The randomized registration clinical trial comparing a combination of VB-111 and paclitaxel to placebo plus paclitaxel is i...
Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 st...
TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company's Chairman of the Board, Dr. Benn...
Vascular Biogenics Ltd. (VBLT) Q3 2020 Earnings Conference Call November 16, 2020 08:30 ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - Chief Executive Officer Amos Ron - Chief Financial Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Swayampakula Ramak...
VBL Therapeutics (VBLT): Q3 GAAP EPS of -$0.12 beats by $0.01.Revenue of $0.19M (+137.5% Y/Y) misses by $0.01M.Press Release For further details see: VBL Therapeutics EPS beats by $0.01, misses on revenue
- Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population with approximately 200 patients enrolled to date - Management to host conf...
TEL AVIV, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive...
TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...